Rucaparib is used in the treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy and for treatment of adult patients with deleterious BRCA mutation (germline and/o somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. Rucaparib Camsylate was developed by Agouron Pharmaceuticals Inc..
The API has now reached off-patent status, after being launched in 2016.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Rucaparib Camsylate and many others, contact info@pharmacheminvestor.com